Publications

CSF ELISA

Wiltfang J, Esselmann H, Bibl M, Hüll M, Hampel H, Kessler H,Frölich L, Schröder J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P.
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load.
J. Neurochem. 2007 May; 101(4): 1053-1059 PubMed

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.
Prediction of Alzheimer’s Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment.
Dement Geriatr Cogn Disord. 2007 Mar; 23: 316-320 PubMed

Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J
Neurochemical diagnosis of Alzheimer’s dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
Neurobiol Aging. 2004 Mar;25(3):273-81 PubMed

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds.
Dement Geriatr Cogn Disord. 2003;15(3):169-76 PubMed

Shoji M
Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness
Front Biosci. 2002 Apr 1;7:d997-1006 PubMed

Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H.
Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer’s disease
Exp Neurol. 2001 Dec;172(2):433-6 PubMed

Jensen M, Hartmann T, Engvall B, Wang R, Uljon SN, Sennvik K, Naslund J, Muehlhauser F, Nordstedt C, Beyreuther K, Lannfelt L.
Quantification of Alzheimer Amyloid β Peptides Ending at residues 40 and 42 by Novel ELISA Systems.
Mol Med. 2000 Apr;6(4):291-302 PubMed

Jensen M, Schroder J, Blomberg M, Engvall B, Pantel J, Ida N, Basun H, Wahlund LO, Werle E, Jauss M, Beyreuther K, Lannfelt L, Hartmann T.
Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer’s disease and declines with disease progression.
Ann Neurol. 1999 Apr;45(4):504-11 PubMed

Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K. 
Analysis of Heterogenous βA4 Peptides in Human Cerebrospinal Fluid and blood by a Newly Developed Sensitive Western Blot Assay.
J Biol Chem. 1996 Sep 13;271(37):22908-14 PubMed

Top